Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
Advertisement
Articles by Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
Advertisement
Latest Updated Articles
Increased Survival Outcomes with Switch Maintenance in mUCPublished: August 26th 2020 | Updated:
Changing the Standard of Care in Metastatic Bladder CancerPublished: August 26th 2020 | Updated:
Safety Data from JAVELIN Bladder 100Published: August 26th 2020 | Updated:
Sequencing Considerations in mUC after Frontline IOPublished: August 26th 2020 | Updated:
Current Status of Therapy: Metastatic Urothelial CancerPublished: August 26th 2020 | Updated:
PD-L1 Expression in Metastatic Urothelial CancerPublished: August 26th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5